Evidence map›Paper›PMID 35269713›Full record

ArticleInternational journal of molecular sciences2022

Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis.

Gareth Morrison, Jonathan Buckley, Dejerianne Ostrow, Bino Varghese, Steven Y Cen, Jeffrey Werbin, Nolan Ericson, Alexander Cunha, Yi-Tsung Lu, Thaddeus George and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Gareth MorrisonDivision of Medical Oncology, Department of Medicine and Department of Biochemistry & Molecular Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
Jonathan BuckleyDepartment of Population and Public Health Sciences, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
Dejerianne OstrowCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0001-6818-1985
Bino VargheseDepartment of Radiology, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
Steven Y CenDepartments of Radiology and Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Jeffrey WerbinRareCyte, Inc., Seattle, WA 98121, USA.
Nolan EricsonRareCyte, Inc., Seattle, WA 98121, USA.
Alexander CunhaDivision of Medical Oncology, Department of Medicine and Department of Biochemistry & Molecular Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0002-7178-8152
Yi-Tsung LuDivision of Medical Oncology, Department of Medicine and Department of Biochemistry & Molecular Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0001-6407-8921
Thaddeus GeorgeRareCyte, Inc., Seattle, WA 98121, USA.ORCID 0000-0002-8123-0240
Jeffrey SmithClinical Sequencing Division, Thermo Fisher Scientific, San Francisco, CA 94080, USA.ORCID 0000-0002-8691-3470
David QuinnDivision of Medical Oncology, Department of Medicine and Department of Biochemistry & Molecular Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
Vinay DuddalwarDepartments of Radiology and Urology, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0002-4808-5715
Timothy TricheCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Amir GoldkornDivision of Medical Oncology, Department of Medicine and Department of Biochemistry & Molecular Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
University of Southern California · USViaCyte (United States) · USChildren's Hospital of Los Angeles · USThermo Fisher Scientific (United States) · US

Funding

Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancerR01CA257610 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DUDDALWAR, VINAY, GOLDKORN, AMIR · 2021 to 2025
$3.4M
NCI NIH HHS R01 CA257610
6 · The paper itself

Abstract

Integrating liquid biopsies of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) with other minimally invasive measures may yield more comprehensive disease profiles. We evaluated the feasibility of concurrent cellular and molecular analysis of CTCs and cfDNA combined with radiomic analysis of CT scans from patients with metastatic castration-resistant PC (mCRPC). CTCs from 22 patients were enumerated, stained for PC-relevant markers, and clustered based on morphometric and immunofluorescent features using machine learning. DNA from single CTCs, matched cfDNA, and buffy coats was sequenced using a targeted amplicon cancer hotspot panel. Radiomic analysis was performed on bone metastases identified on CT scans from the same patients. CTCs were detected in 77% of patients and clustered reproducibly. cfDNA sequencing had high sensitivity (98.8%) for germline variants compared to WBC. Shared and unique somatic variants in PC-related genes were detected in cfDNA in 45% of patients (MAF > 0.1%) and in CTCs in 92% of patients (MAF > 10%). Radiomic analysis identified a signature that strongly correlated with CTC count and plasma cfDNA level. Integration of cellular, molecular, and radiomic data in a multi-parametric approach is feasible, yielding complementary profiles that may enable more comprehensive non-invasive disease modeling and prediction.

Indexed as

Cell-Free Nucleic AcidsNeoplastic Cells, CirculatingProstatic NeoplasmsBiomarkers, TumorHumansLiquid BiopsyMaleBiomarkers, TumorCell-Free Nucleic Acidscell-free DNAcirculating tumor cellsmetastatic prostate cancerradiomics

Identifiers

PMID35269713
PMCPMC8910093
OpenAlexW4214704581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.